Publications
2022
- Dr. Jeffrey Cummings: Aducanumab: Appropriate use recommendations
- Dr. Jeffrey Cummings: Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
- Dr. Jeffrey Cummings: Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease
- Dr. Jeffrey Cummings: Alzheimer’s Disease Drug Development Pipeline:2022
- Dr. Jeffrey Cummings: Investing in Late-Life Brain Capital
- Dr. Jeffrey Cummings: The role of basket trials in drug development for neurodegenerative disorders
- Dr. Jefferson Kinney & Dr. Jeffrey Cummings: Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease
2021
- Dr. Jeffrey Cummings: Affective Computing for Late-Life Mood and Cognitive Disorders
- Dr. Jeffrey Cummings: Innovative Therapeutic Development Programme for the Treatment of Early Alzheimer’s Disease: Lecanemab (BAN2401)
- Dr. Jeffrey Cummings, Dr. Jefferson Kinney, & Dr. Samantha John: Nevada exploratory Alzheimer’s disease research center: Advancing dementia care in rural communities
- Dr. Jeffrey Cummings: Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease
- Dr. Jeffrey Cummings: Development and assessment of a brief screening tool for psychosis in dementia
- Dr. Jeffrey Cummings: The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
- Dr. Jeffrey Cummings: Disease modification is not all — we need symptomatic therapies for Alzheimer disease
- Dr. Jeffrey Cummings: A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
- Dr. Jeffrey Cummings: Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial
- Dr. Jeffrey Cummings: The Amyloid-β Pathway in Alzheimer’s Disease
- Dr. Jeffrey Cummings: The costs of developing treatments for Alzheimer's disease: A retrospective exploration
- Dr. Jeffrey Cummings: Estimating Progression Rates Across the Spectrum of Alzheimer's Disease for Amyloid-Positive Individuals Using National Alzheimer's Coordinating Center Data
- Dr. Jeffrey Cummings: Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease
- Dr. Jeffrey Cummings: Why aducanumab is important
- Dr. Jeffrey Cummings: Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project
- Dr. Jeffrey Cummings: Aducanumab: Appropriate use recommendation
- Dr. Jeffrey Cummings: Aducanumab: Appropriate Use Recommendations
- Dr. Jeffrey Cummings: Trial of Pimavanserin in Dementia-Related Psychosis
- Dr. Kinney & Dr. Hyman: Altered theta rhythm and hippocampal-cortical interactions underlie working memory deficits in a hyperglycemia risk factor model of Alzheimer’s disease
- Dr. Donnamarie: The association between hand disease severity and fatigue in individuals with systemic sclerosis: a scoping review
- Dr. Jeffrey Cummings: Assessing Clinical Change in Individuals Exposed to Repetitive Head Impacts: The Repetitive Head Impact Composite Index
- Dr. Jeffrey Cummings: Diagnostic criteria for apathy in neurocognitive disorders
- Dr. Jeffrey Cummings: Developing the ATX(N) classification for use across the Alzheimer disease continuum
- Dr. Jeffrey Cummings: Novel Treatments for Alzheimer Disease Disorders
- Dr. Jeffrey Cummings: AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery
- Dr. Jefferson Kinney, Dr. Arpita Basu, Dr. Arnold Salazar: Dietary Strawberries Improve Cardiometabolic Risks in Adults with Obesity and Elevated Serum LDL Cholesterol in a Randomized Controlled Crossover Trial
- Dr. Jeffrey Cummings: Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer’s disease: A randomized, placebo-controlled, phase 3 clinical trial (MINDSET)
- Dr. Jeffrey Cummings: State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer’s disease
- Dr. Jeffrey Cummings: Alzheimer's disease drug development pipeline: 2021
- Dr. Jeffrey Cummings: Who funds Alzheimer's disease drug development?
- Dr. Jeffrey Cummings: Value-Generating Exploratory Trials in Neurodegenerative Dementias
- Dr. Jeffrey Cummings: Diagnostic criteria for apathy in neurocognitive disorders
- Dr. Jeffrey Cummings: Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
- Dr. Jeffrey Cummings: Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group
- Dr. Jeffrey Cummings: A 36-week multicenter, randomized, double-blind, placebo-controlled, parallelgroup, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
- Dr. Jeffrey Cummings: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
- Dr. Jeffrey Cummings, Dr. Jefferson Kinney, Dr. Kate Zhong: Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia
- Dr. Jefferson Kinney: Alterations of GABA B receptors in the APP/PS1 mouse model of Alzheimer's disease
- Dr. Jeffrey Cummings: New approaches to symptomatic treatments for Alzheimer’s disease
- Dr. Jeffrey Cummings: A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages
- Dr. Jeffrey Cummings: National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome
- Dr. Jeffrey Cummings Building brain capital
2020
- Dr. Jeffrey Cummings: Drug repositioning and repurposing for Alzheimer disease.
- Dr. Jeffrey Cummings: Translational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach
- Dr. Jeffrey Cummings: The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases
- Dr. Jeffrey Cummings: Brain health INnovation Diplomacy: a model binding diverse disciplines to manage the promise and perils of technological innovation
- Dr. Jeffrey Cummings: FLAME: A computerized neuropsychological composite for trials in early dementia
- Dr. Jeffrey Cummings: A Brain Capital Grand Strategy: toward economic reimagination
- Dr. Jeffrey Cummings: Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer’s Disease
- Dr. Jeffrey Cummings: BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain
- Dr. Jeffrey Cummings: Open Peer Commentary to “Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019”
- Dr. Jeffrey Cummings: Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition
- Dr. Jeffrey Cummings: Collaboration between the FDA and industry is essential to foster innovation in Alzheimer’s treatments
- Dr. Jeffrey Cummings: An Actigraphy-Based Validation Study of the Sleep Disorder Inventory in the Nursing Home.
- Dr. Jeffrey Cummings: Non-Amyloid Approaches to Disease Modification for Alzheimer’s disease.
- Dr. Jeffrey Cummings: The role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs.
- Dr. Jeffrey Cummings: Translational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach.
- Justin Bauzon & Dr. Jeffrey Cummings: Repurposed agents in the Alzheimer’s disease drug development pipeline.
TRC-PAD stands for Trial-Ready Cohort for Preclinical and prodromal Alzheimer's disease. It is an innovative NIA-funded way of assessing patients on line, using an algorithm to determine which are most likely to have Alzheimer's and then referring that selected group to sites for trials. The idea is to facilitate trial recruitment, the slowest part of any current Alzheimer trial. Attached is a set of 5 papers just published in J Prevention of Alzheimer's Disease (JPAD) about this project.
2019
- Dr. Jeffery Cummings: Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/CTAD Task Force.
- Dr. Jeffery Cummings: Alzheimer's disease drug development pipeline: 2019.
- Dr. Jeffery Cummings: A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms.
- Dr. Jeffery Cummings: Advances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases.
- Dr. Jeffery Cummings: Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease.
- Donna Coasta: The Occupational Therapy Manager, 6th Ed. Bethesda, MD: AOTA Press.
- Donna Coasta: Chapter 43. Management of Fieldwork Education. In Jacobs, K., McCormack, G. The Occupational Therapy Manager, 6th Ed. Bethesda, MD: AOTA Press.
- Donna Coasta: Chapter 42. Occupational Therapy Assistants as Managers. In Jacobs, K., McCormack, G., (Lead Eds.). The Occupational Therapy Manager, 6th Ed. Bethesda, MD: AOTA Press.